- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06270173
Post-markedsundersøgelse af Tripod-Fix Vertebral Body Augmentation System i osteoporotiske vertebrale kompressionsfrakturer
En prospektiv, multicenter, open-label, post-markedsundersøgelse for at evaluere effektiviteten og sikkerheden af Tripod-Fix vertebral body augmentation-systemet i osteoporotiske vertebrale kompressionsfrakturer
The objective of this Post-Market Clinical Follow-Up Study is to evaluate the safety and performance of the Tripod-Fix in the treatment of vertebral compression fractures (VCF) resulting from osteoporosis.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
This study is a prospective, multicenter, open-label, single-arm, PMCF study. The sample size for this study will be 50 patients. Eligible patients will be treated with Tripod-Fix on Day 0 and will be followed for a total of 12 months.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Baden-Wurttemberg
-
Friedrichshafen, Baden-Wurttemberg, Tyskland, 88048
- Klinikum Friedrichshafen
-
Mannheim, Baden-Wurttemberg, Tyskland, 68167
- University Hospital Mannheim
-
-
Hesse
-
Frankfurt am Main, Hesse, Tyskland, 60596
- Johann Wolfgang Goethe University Frankfurt/Main
-
-
North Rhine-Westphalia
-
Mechernich, North Rhine-Westphalia, Tyskland, 53894
- Krankenaus Mechernich
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
Provision of signed and dated informed consent form prior to any study procedures
-
Stated willingness to comply with all study procedures and availability for the duration of the study
-
Skeletally mature males and females
-
1 painful VCF which meets all of the following criteria:
- Fracture due to diagnosed or presumed underlying osteoporosis (T-score < -2.5 points)
- VCF between T6 and L5
- VCF shows loss of height in the anterior, mid or posterior third of the vertebral body from an estimated pre-fracture configuration, but no more than 50% based on X-ray, CT or MRI at baseline.
- The Index fracture is acute or persistent (not healed), as demonstrated by MRI (or bone scan if the patient is contraindicated for MRI).
-
Investigator believes target vertebral body is suitable for Tripod-Fix procedure (e.g., appropriate pedicle diameter) assessed on radiography preoperative.
Exclusion Criteria:
Tripod-Fix is not indicated for any other application other than that for which it is designed. contraindications for Tripod-Fix include, but are not limited to: .
- Patient presenting a loss of vertebral height >50% compared to estimated pre-fracture height
- Sclerotic fracture
- Patient with a prior history of intolerance or of allergic reaction to titanium and/or one of the components of the PMMA cement
- Patient suffering from irreversible coagulopathy or undergoing anticoagulant treatment at the moment of surgery or at least 8 days prior to inclusion
- Active infection (systemic or in the target vertebra)
- Patient suffering from a severe or uncontrolled systemic disease
- Patient presenting a pathological fracture with the presence of a mass within the spinal canal
- Patient presenting neurological damage caused by vertebral fracture
- Patient pregnant or likely to be so or breastfeeding
- Patient vertebral anatomy not compatible with the size of the implant or instrumentation
- Fracture geometry making the insertion of the implant impossible
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Intervention
Tripod-Fix will be used to treat osteoporotic vertebral compression fractures. |
The Tripod-Fix is a permanent implant used for vertebral augmentation in patients with osteoporotic vertebral compression fractures. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Proportion of participants with study success
Tidsramme: 12 months post-procedure
|
Study success is defined as follows:
|
12 months post-procedure
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Studieleder: Te-Yang Tsai, Wiltrom Co., Ltd.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
- TWM-C-2202
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .